Review

Can baxdrostat redefine blood pressure control in resistant and uncontrolled hypertension? a systematic review, meta-analysis, and trial sequential analysis.

B. Khan Muhammad Yahya H. Khan Miguel Alejandro Rivas Perez T. I. Qazi Humaira Obaid Muhammad Mustafa Khan M. Amjad Muhammad Faaz Khan A. Khan Muhammad Junaid Khan Sajjad Khan A. A. Malik Fatima Haneef M. H. Khattak Atta ur Rahman S. Khan Saeeda Zahid

Jul 2026 · Naunyn-Schmiedeberg's Archives of Pharmacology · 1 citation · 18 references

Medicine

TL;DR

Baxdrostat, particularly at 2 mg, provides clinically meaningful BP reductions, and serious safety outcomes remain entirely comparable to control, which highlights a reassuring safety profile.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Aug 2026

Efficacy and Safety of Baxdrostat for Patients With Uncontrolled or Resistant Hypertension: A Systematic Review and Meta-Analysis.

Baxdrostat lowers blood pressure and aldosterone levels in uncontrolled and resistant hypertension but increases potassium and modestly reduces eGFR, supporting careful laboratory monitoring and longer trials to evaluate long-term clinical outcomes.

A. Gadelmawla, A. Hageen, R. Rateb et al. · Cardiology in Review · 0 citations

Review Sep 2026

Efficacy and Safety of Baxdrostat in Hypertension: A GRADE-Assessed Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Findings strengthen the evidence for selective aldosterone synthase inhibition as a therapeutic approach for aldosterone-mediated hypertension and suggest that baxdrostat may provide an additional treatment option, particularly for patients who remain uncontrolled or cannot tolerate mineralocorticoid receptor antagonis...

Muhammad Burhan, Z. Shahid, M. Naveed et al. · The Annals of Pharmacotherap... · 0 citations

Review Aug 2026

Dose-response efficacy and safety of the aldosterone synthase inhibitor baxdrostat in resistant hypertension: a systematic review and network meta-analysis.

Baxdrostat 1 mg and 2 mg significantly increased overall adverse events and hyperkalemia, whereas serious adverse events were not significantly increased, and both higher doses significantly increased hyperkalemia risk.

M. Shahzaib, Hafsa Ali, Muhammad Roshaan et al. · Naunyn-Schmiedeberg's Archiv... · 0 citations

Meta-analysis Open access Sep 2026

Efficacy and safety of zilebesiran in adults with hypertension: a systematic review and meta-analysis of randomized controlled trials

Overall, zilebesiran produced significant and consistent BP reductions, especially in ambulatory measures, with a favorable safety profile, and builds on previous meta-analyses that included only 2 RCTs; this updated analysis reflects the need for novel therapeutic options.

Muhammad Hussain, Muhammad Hassan, Asharib Sohaib et al. · European Journal of Clinical... · 1 citation

Review Open access Jul 2026

Efficacy and Safety of SGLT-2 Inhibitors in Patients with Uncontrolled or Resistant Hypertension: A Pilot Meta-Analysis of Randomized Clinical Trials.

SGLT-2 inhibitors provide a modest incremental benefit in lowering office systolic blood pressure for patients with uncontrolled or resistant hypertension on multidrug regimens with an overall acceptable safety profile.

Omer Mohammed, Sun Hyeok Kim, A. Karthikeyan et al. · High Blood Pressure & Cardio... · 0 citations

Review Jul 2026

Efficacy and Safety of Selective Aldosterone Synthase Inhibitors in Uncontrolled Hypertension: A Systematic Review and Dose-Specific Network Meta-Analysis of Randomized Controlled Trials.

Selective aldosterone synthase inhibitors (ASIs), including baxdrostat and lorundrostat, target CYP11B2 while sparing cortisol synthesis, offering a novel strategy for resistant and uncontrolled hypertension. Yet existing meta-analyses have included nonselective agents or omitted the latest phase 3 data. We searched Pu...

N. Hammad, M. Elkasaby, A. Gadelmawla et al. · Cardiology in Review · 1 citation